Serum Institute of India Pvt. Ltd.
Serum Institute of India is dedicated to developing vaccines that meet the specific needs of different segments of the global population, including collaborations with international agencies. Its mission is to provide protection from birth onwards through innovative vaccine development, research, social responsibility initiatives, and green energy projects. The company is the world's largest vaccine manufacturer by volume, producing over 1.5 billion doses and supplying to around 170 countries. It has a strong focus on affordability, quality, and social impact, with extensive achievements, awards, and collaborations in the vaccine and biopharmaceutical sectors.
Industries
Nr. of Employees
Very Large (1000+)
Serum Institute of India Pvt. Ltd.
Products
Hexavalent combination pediatric vaccine (DTP, HepB, IPV, Hib)
Combination vaccine for active immunization of infants against diphtheria, tetanus, pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b in a three-dose primary schedule with booster recommendations.
Recombinant protein VLP malaria vaccine
Recombinant, adjuvanted malaria vaccine comprising a circumsporozoite-derived antigen expressed as virus-like particles in yeast.
Quadrivalent recombinant HPV vaccine
Quadrivalent recombinant human papillomavirus vaccine covering multiple serotypes for prevention of HPV-related disease.
Adjuvanted recombinant nanoparticle COVID-19 vaccine
Adjuvanted recombinant protein nanoparticle vaccine formulation developed for SARS-CoV-2, including variant-adapted formulations.
Adenoviral vector COVID-19 vaccine (recombinant viral vector)
Recombinant adenoviral vector-based SARS-CoV-2 vaccine used for primary immunization against COVID-19.
Live attenuated oral rotavirus vaccine (freeze-dried and liquid)
Live attenuated oral vaccine for prevention of rotavirus gastroenteritis, available in freeze-dried and liquid oral presentations.
Hexavalent combination pediatric vaccine (DTP, HepB, IPV, Hib)
Combination vaccine for active immunization of infants against diphtheria, tetanus, pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b in a three-dose primary schedule with booster recommendations.
Recombinant protein VLP malaria vaccine
Recombinant, adjuvanted malaria vaccine comprising a circumsporozoite-derived antigen expressed as virus-like particles in yeast.
Quadrivalent recombinant HPV vaccine
Quadrivalent recombinant human papillomavirus vaccine covering multiple serotypes for prevention of HPV-related disease.
Adjuvanted recombinant nanoparticle COVID-19 vaccine
Adjuvanted recombinant protein nanoparticle vaccine formulation developed for SARS-CoV-2, including variant-adapted formulations.
Adenoviral vector COVID-19 vaccine (recombinant viral vector)
Recombinant adenoviral vector-based SARS-CoV-2 vaccine used for primary immunization against COVID-19.
Live attenuated oral rotavirus vaccine (freeze-dried and liquid)
Live attenuated oral vaccine for prevention of rotavirus gastroenteritis, available in freeze-dried and liquid oral presentations.
Services
Preclinical and clinical development services (GLP/GCP compliance)
Execution of GLP-compliant preclinical studies and GCP-compliant clinical trials, including toxicology studies and staged clinical evaluation.
Global vaccine supply, procurement support and distribution
Manufacture, packaging and international distribution of vaccines in multiple presentations and dose formats, supporting national immunization programmes and international procurement agencies.
Technology transfer, antigen component manufacturing and contract manufacturing
Inbound and outbound technology transfer, process scale-up and contract manufacture of vaccine components and finished-dose products to support partner supply commitments.
Emergency and pandemic response manufacturing
Rapid scale-up and prioritized production services for outbreak response, including expedited manufacturing, regulatory engagement and logistic support for emergency immunization programs.
Support for collaborative adjuvanted vaccine development and clinical trials
Partnership-based support for developing adjuvanted vaccine candidates, formulation optimization and execution of early-phase clinical trials in collaboration with external partners.
Regulatory submission support including eCTD and WHO prequalification
Preparation and electronic submission of regulatory dossiers to national and international agencies and support for WHO prequalification processes.
Preclinical and clinical development services (GLP/GCP compliance)
Execution of GLP-compliant preclinical studies and GCP-compliant clinical trials, including toxicology studies and staged clinical evaluation.
Global vaccine supply, procurement support and distribution
Manufacture, packaging and international distribution of vaccines in multiple presentations and dose formats, supporting national immunization programmes and international procurement agencies.
Technology transfer, antigen component manufacturing and contract manufacturing
Inbound and outbound technology transfer, process scale-up and contract manufacture of vaccine components and finished-dose products to support partner supply commitments.
Emergency and pandemic response manufacturing
Rapid scale-up and prioritized production services for outbreak response, including expedited manufacturing, regulatory engagement and logistic support for emergency immunization programs.
Support for collaborative adjuvanted vaccine development and clinical trials
Partnership-based support for developing adjuvanted vaccine candidates, formulation optimization and execution of early-phase clinical trials in collaboration with external partners.
Regulatory submission support including eCTD and WHO prequalification
Preparation and electronic submission of regulatory dossiers to national and international agencies and support for WHO prequalification processes.
Expertise Areas
- Industrial-scale vaccine manufacturing
- Pandemic and outbreak manufacturing surge capacity
- Recombinant subunit and VLP vaccine platforms
- Polysaccharide-protein conjugate vaccine development
Key Technologies
- Bioreactor-based cell culture (mammalian and yeast systems)
- Virus-like particle (VLP) production
- Adenoviral and other viral vector manufacturing
- Recombinant protein nanoparticle vaccine platforms